A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Inclusion Criteria:

• Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)

  • Patients on hemodialysis (HD) or peritoneal dialysis (PD)
  • Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent

Exclusion Criteria

1. Acute Kidney Injury (AKI) without underlying chronicity
2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
3. Refusal or inability to provide consent
4. Current enrollment in an interventional trial that restricts real-world data collection
5. Life expectancy < 3 months, where follow-up is not feasible
6. Known contraindications to Daprodustat as per local prescribing information

patients with Chronic Kidney Disease (CKD) anemia requiring anemia treatment